BNTX
BioNTech SE American Depositary Share
Nasdaq · usd
BioNTech SE American Depositary Share (BNTX) trades at $87.24 (-0.99%) as of 2:23:59 PM EDT on Oct 26, 2026, -11.55% over the past month. Market cap is $22.13B, with 3.1 days to cover in short interest.
Stock performance
How BioNTech SE American Depositary Share (BNTX) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.11%
- 1W
- -2.32%
- 1M
- -11.55%
- YTD
- -8.47%
- 1Y
- -17.83%
- 52-wk range
- $79.52 – $124.00
Key statistics
Today's trading snapshot for BNTX: day range, open, previous close, volume and market cap.
- Day range
- $85.85 – $88.87
- Open
- $86.00
- Prev close
- $88.12
- Volume
- 879.03K
- Market cap
- $22.13B
- Shares out
- 252.88M
Dividend history and stock splits
BioNTech SE American Depositary Share's recent dividend payments and stock splits.
Dividends
- $2.13ex-div Jun 2, 2022
Splits
No recent splits.
BNTX short interest
How heavily BNTX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.1
- Short interest
- 2.5M
- Avg volume
- 799.04K
As of · reported to FINRA twice monthly.
BNTX news
The latest news and headlines about BioNTech SE American Depositary Share (BNTX).
- BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast CancernegativeGlobeNewswire Inc.· Oct 26, 2026
- BioNTech und DualityBio geben Topline-Ergebnisse der globalen klinischen Phase-3-Studie DYNASTY-Breast02 für Trastuzumab Pamirtecan bei metastasiertem HR+/HER2-low-Brustkrebs bekanntnegativeGlobeNewswire Inc.· Oct 26, 2026
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapypositiveGlobeNewswire Inc.· Oct 25, 2026
- BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und ChemotherapiepositiveGlobeNewswire Inc.· Oct 25, 2026
- Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak ReportsnegativeThe Motley Fool· Oct 22, 2026
Frequently asked questions
What is the BioNTech SE American Depositary Share (BNTX) stock price today?
BioNTech SE American Depositary Share (BNTX) is trading at $87.24 (-0.99% on the day) as of 2:23:59 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is BioNTech SE American Depositary Share?
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid.
What is the short interest in BNTX?
As of Sep 30, 2026, BNTX has 2.5M shares short and 3.1 days to cover.
Does BioNTech SE American Depositary Share (BNTX) pay a dividend?
Yes. BioNTech SE American Depositary Share (BNTX)'s most recent dividend was $2.13 per share, with an ex-dividend date of Jun 2, 2022. Full BNTX dividend history is available from the Massive API.
What exchange is BNTX listed on?
BioNTech SE American Depositary Share (BNTX) trades on Nasdaq in USD.
Build with AI
Build an analysis of BNTX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BNTX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.